



---

## Elekta Collaborate on Safer Dose Radiation Therapy Technology



---

Elekta and ScandiDos AB have entered into a non-exclusive global agreement to distribute ScandiDos's Delta4PT quality assurance (QA) tool. Delta4PT can be used with Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) techniques to provide complete pre-treatment QA that ensures that the dose prescribed in treatment plans is delivered accurately and safely to patients.

"We're very pleased that Elekta, a true innovator and leader in the radiation oncology industry recognized the value of our ScandiDos Delta4PT QA solution," says Gorgen Nilsson, CEO at ScandiDos. "We hope this is the beginning of an ongoing relationship with Elekta and its customers as they strive to make radiation therapy the safest, most effective tool in the fight against cancer and other serious diseases."

Delta4PT, used to verify IMRT and arc therapy delivery techniques since 2006, enables clinicians to verify dose delivery without compromises, in 3D; instantly analyze and approve plans; evaluate the clinical significance of deviation; and identify the cause of deviations. The benefits are improved efficiency by increasing the volume of patients that can be treated as well as enhanced verification accuracy – enabling more qualified QA decisions to be made.

The agreement will make Delta4PT accessible to the Elekta customer network, further complementing the Elekta QA solutions portfolio and widening the breadth of choices for its customers.

"As an open source, vendor neutral company, our partnership with ScandiDos ensures that our customers can select QA solutions that best meet their needs and clinical resources," says Brett North, Marketing Director, Oncology at Elekta.

Published on : Mon, 30 May 2011